Literature DB >> 21414905

Neural correlates of an injury-free model of central sensitization induced by opioid withdrawal in humans.

Vishvarani Wanigasekera1, Michael C H Lee, Richard Rogers, Philip Hu, Irene Tracey.   

Abstract

Preclinical evidence suggests that opioid withdrawal induces central sensitization (CS) that is maintained by supraspinal contributions from the descending pain modulatory system (DPMS). Here, in healthy human subjects we use functional magnetic resonance imaging to study the supraspinal activity during the withdrawal period of the opioid remifentanil. We used a crossover design and thermal stimuli on uninjured skin to demonstrate opioid withdrawal-induced hyperalgesia (OIH) without a CS-inducing peripheral stimulus. Saline was used in the control arm to account for effects of time. OIH in this injury-free model was observed in a subset of the healthy subjects (responders). Only in these subjects did opioid infusion and withdrawal induce a rise in activity in the mesencephalic-pontine reticular formation (MPRF), an area of the DPMS that has been previously shown to be involved in states of CS in humans, which became significant during the withdrawal phase compared with nonresponders. Paradoxically, this opioid withdrawal-induced rise in MPRF activity shows a significant negative correlation with the behavioral OIH score indicating a predominant inhibitory role of the MPRF in the responders. These data illustrate that in susceptible individuals central mechanisms appear to regulate the expression of OIH in humans in the absence of tissue injury, which might have relevance for functional pain syndromes where a peripheral origin for the pain is difficult to identify.

Entities:  

Mesh:

Year:  2011        PMID: 21414905      PMCID: PMC3095083          DOI: 10.1523/JNEUROSCI.5412-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  47 in total

1.  Temporal autocorrelation in univariate linear modeling of FMRI data.

Authors:  M W Woolrich; B D Ripley; M Brady; S M Smith
Journal:  Neuroimage       Date:  2001-12       Impact factor: 6.556

Review 2.  Human surrogate models of neuropathic pain.

Authors:  Thomas Klein; Walter Magerl; Roman Rolke; Rolf-Detlef Treede
Journal:  Pain       Date:  2005-06       Impact factor: 6.961

Review 3.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

4.  Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.

Authors:  Stephen M Smith; Thomas E Nichols
Journal:  Neuroimage       Date:  2008-04-11       Impact factor: 6.556

5.  Lack of tolerance in peripheral opioid analgesia in mice.

Authors:  S Tokuyama; M Inoue; T Fuchigami; H Ueda
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

6.  Secondary hyperalgesia to punctate mechanical stimuli. Central sensitization to A-fibre nociceptor input.

Authors:  E A Ziegler; W Magerl; R A Meyer; R D Treede
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

7.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

8.  Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia.

Authors:  David D Hood; Regina Curry; James C Eisenach
Journal:  Anesth Analg       Date:  2003-09       Impact factor: 5.108

9.  Influence of arthritis on descending modulation of nociception from the paraventricular nucleus of the hypothalamus.

Authors:  Filipa Pinto-Ribeiro; Osei B Ansah; Armando Almeida; Antti Pertovaara
Journal:  Brain Res       Date:  2007-12-28       Impact factor: 3.252

10.  Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal.

Authors:  Martin S Angst; Wolfgang Koppert; Ilka Pahl; David J Clark; Martin Schmelz
Journal:  Pain       Date:  2003-11       Impact factor: 6.961

View more
  14 in total

1.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

2.  Resting Functional Connectivity of the Periaqueductal Gray Is Associated With Normal Inhibition and Pathological Facilitation in Conditioned Pain Modulation.

Authors:  Daniel E Harper; Eric Ichesco; Andrew Schrepf; Johnson P Hampson; Daniel J Clauw; Tobias Schmidt-Wilcke; Richard E Harris; Steven E Harte
Journal:  J Pain       Date:  2018-01-31       Impact factor: 5.820

3.  Opioid-Induced Hyperalgesia Is Associated with Dysregulation of Circadian Rhythm and Adaptive Immune Pathways in the Mouse Trigeminal Ganglia and Nucleus Accumbens.

Authors:  Pan Zhang; Laura S Moye; Bruce R Southey; Isaac Dripps; Jonathan V Sweedler; Amynah Pradhan; Sandra L Rodriguez-Zas
Journal:  Mol Neurobiol       Date:  2019-05-25       Impact factor: 5.590

4.  Paracetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey.

Authors:  David André Barrière; Fawzi Boumezbeur; Romain Dalmann; Roberto Cadeddu; Damien Richard; Jérémy Pinguet; Laurence Daulhac; Philippe Sarret; Kevin Whittingstall; Matthieu Keller; Sébastien Mériaux; Alain Eschalier; Christophe Mallet
Journal:  Br J Pharmacol       Date:  2020-01-22       Impact factor: 8.739

5.  The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males.

Authors:  David Andrew Tompkins; Michael T Smith; George E Bigelow; Ruin Moaddel; Swarajya Lakshmi Vatem Venkata; Eric C Strain
Journal:  Clin J Pain       Date:  2014-01       Impact factor: 3.442

Review 6.  Imaging pain: a potent means for investigating pain mechanisms in patients.

Authors:  M C Lee; I Tracey
Journal:  Br J Anaesth       Date:  2013-07       Impact factor: 9.166

7.  Pain, decisions, and actions: a motivational perspective.

Authors:  Katja Wiech; Irene Tracey
Journal:  Front Neurosci       Date:  2013-04-02       Impact factor: 4.677

8.  Disambiguating Pharmacodynamic Efficacy from Behavior with Neuroimaging: Implications for Analgesic Drug Development.

Authors:  Vishvarani Wanigasekera; Melvin Mezue; Jesper Andersson; Yazhuo Kong; Irene Tracey
Journal:  Anesthesiology       Date:  2016-01       Impact factor: 7.892

9.  Baseline reward circuitry activity and trait reward responsiveness predict expression of opioid analgesia in healthy subjects.

Authors:  Vishvarani Wanigasekera; Michael C Lee; Richard Rogers; Yazhuo Kong; Siri Leknes; Jesper Andersson; Irene Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

10.  Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI.

Authors:  Robert Gear; Lino Becerra; Jaymin Upadhyay; James Bishop; Diana Wallin; Gautam Pendse; Jon Levine; David Borsook
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.